1;Cover;1<br />2;Front matter;4<br />3;Contents;6<br />4;Preface;8<br />5;Sonography of Normal and Abnormal Thyroid and Parathyroid Glands;10<br />5.1;Abstract;10<br />5.2;Thyroid Ultrasonography;11<br />5.3;Parathyroid Ultrasonography;20<br />5.4;References;23<br />6;Computed Tomography and Magnetic Resonance Imaging of the Thyroid and Parathyroid Glands;25<br />6.1;Abstract;25<br />6.2;Thyroid;25<br />6.3;Parathyroid;28<br />6.4;References;31<br />7;Role of Nuclear Medicine in the Diagnosis of Benign Thyroid Diseases;33<br />7.1;Abstract;33<br />7.2;Nuclear Medicine: Radiopharmacology and Methods;34<br />7.3;Devices;34<br />7.4;Radiopharmaceuticals;35<br />7.5;Technetium-99m;35<br />7.6;Measurement of Technetium Uptake;35<br />7.7;Iodine Isotopes: 123 I and 131 I;35<br />7.8;Measurement of Iodine Uptake;36<br />7.9;Thyroid Scintigraphy;36<br />7.10;Other Thyroid Examinations and Tests;37<br />7.11;Benign Thyroid Diseases and Indications for Nuclear Medicine Tests;40<br />7.12;Acknowledgements;44<br />7.13;References;44<br />8;Hybrid Molecular Imaging in Differentiated Thyroid Carcinoma;46<br />8.1;Abstract;46<br />8.2;The Use of Radioiodine in Thyroid Carcinomas;47<br />8.3;Single-Photon Emission Computed Tomography/Computed Tomography in Differentiated Thyroid Carcinoma;49<br />8.4;Position Emission Tomography/Computed Tomography in Differentiated Thyroid Carcinoma;51<br />8.5;Conclusions;52<br />8.6;References;53<br />9;Endoscopic Ultrasound in Endocrinology: Imaging of the Adrenals and the Endocrine Pancreas;55<br />9.1;Abstract;55<br />9.2;Technical Details;56<br />9.3;Resolution;57<br />9.4;Indications and Typical Findings;57<br />9.5;Conclusion;62<br />9.6;References;62<br />10;Adrenal Imaging: Magnetic Resonance Imagingand Computed Tomography;64<br />10.1;Abstract;64<br />10.2;Introduction;64<br />10.3;Benign Lesions;70<br />10.4;Malignant Lesions;73<br />10.5;Image-Guided Intervention;75<br />10.6;References;77<br />11;Adrenal Molecular Imaging;79<br />11.1;Abstract;79<br />11.2;Molecular Imaging Techniques;80<br />11.3;Adrenal Incidentalomas;81<br />11.4;Molecular Imaging of Adrenal Tumors;82<br />11.5;Primary Aldosteronism;83<br />11.6;11 C-Metomidate PET in Adrenocortical Cancer;83<br />11.7;123 I-Metomidate SPECT;84<br />11.8;Pheochromocytoma;84<br />11.9;References;87<br />12;Gonadal Imaging in Endocrine Disorders;89<br />12.1;Abstract;89<br />12.2;Male Gonads;89<br />12.3;Female Gonads;97<br />12.4;References;104<br />13;Magnetic Resonance Imaging of Pituitary Tumors;106<br />13.1;Abstract;106<br />13.2;The Normal Pituitary Gland;106<br />13.3;Pituitary Adenomas;108<br />13.4;Collision Lesions of the Pituitary Region;120<br />13.5;The Postoperative Sella;120<br />13.6;Differential Diagnosis of Sellar Space-Occupying Lesions;123<br />13.7;References;128<br />14;Intraoperative Magnetic Resonance Imaging for Pituitary Adenomas;130<br />14.1;Abstract;130<br />14.2;Scanners and Setups;131<br />14.3;Results of Low-Field Studies;133<br />14.4;Results of High-Field Studies;135<br />14.5;Use of Neuronavigation;136<br />14.6;Intraoperative Imaging and Endoscopic Surgery;139<br />14.7;Conclusions;139<br />14.8;References;139<br />15;Molecular Imaging of Pituitary Pathology;142<br />15.1;Abstract;142<br />15.2;Receptor Imaging of Pituitary Tumors;143<br />15.3;Dopamine D2 Receptor Imaging of Pituitary Adenomas;143<br />15.4;Dopamine D2 Receptor Imaging of Pituitary Carcinomas;143<br />15.5;Somatostatin Receptor Scintigraphy of Pituitary Disorders;144<br />15.6;18F-Fluorodeoxy-D-Glucose Positron EmissionTomography and Pituitary Pathology;147<br />15.7;L - 11 C-Methionine Positron Emission Tomography and Pituitary Pathology;149<br />15.8;Conclusions;149<br />15.9;References;149<br />16;Imaging of Neuroendocrine Tumors;151<br />16.1;Abstract;151<br />16.2;Imaging Techniques;152<br />16.3;Neuroendocrine Tumor Characteristics, Presentationand Image Findings;156<br />16.4;Imaging in Therapy Monitoring;158<br />16.5;References;159<br />17;Author Index;161<br />18;Subject Index;162<br />19;Cover;166